Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-06-07
1998-12-01
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514513, 514515, 514529, 514538, 514563, 514567, A61K 3121, A01N 4740
Patent
active
058439943
ABSTRACT:
Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents including retinoids, hydroxyurea, and flavonoids. Intravesicle methods of treatment of cancers phenylacetate. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention. A product as a combined preparation of phenylacetate and a retinoid, hydroxyurea, or flavonid (or other mevalonate pathway inhibitor) for simultaneous, separate, or sequential use in treating a neoplastic condition in a subject. Methods of modulating lipid metabolism and/or reducing serum triglycerides in a subject using phenylacetate.
REFERENCES:
patent: 3973022 (1976-08-01), Goschke
patent: 3976673 (1976-08-01), Pifferi
patent: 3998966 (1976-12-01), Fried et al.
patent: 4028404 (1977-06-01), Bays et al.
patent: 4282214 (1981-08-01), Flora et al.
patent: 4457942 (1984-07-01), Brusilow
patent: 4470970 (1984-09-01), Burzynski
patent: 4720506 (1988-01-01), Munakata et al.
patent: 5244922 (1993-09-01), Burzynski
Burzynski, S.R. et al., Preclinical studies on antineoplaston as2-1 and antineoplaston AS2-5, Drugs Exptl. Clin. Res., Supplemental 1, XII:11-16 (1986).
Timothy J. Ley, et al., 5-Azacytidine Selectively Increases .gamma.-globin Synthesis in a Patient with .beta..sup.+ Thalassemia, New England Journal of Medicine, vol. 307:1469-1475 (Dec. 8, 1982).
Michael B. Sporn, et al., Chemoprevention of Cancer with Retinoids, Federation Proceedings, vol. 38:2528-2534 (Oct. 1979).
Richard L. Momparler, et al., Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia, Pharmac. Ther., vol. 30:277-286 (1985).
Gary J. Kelloff, et al., Chemoprevention Clinical Trials, Mutation Research, vol. 267:291-295 (1992).
I. Bernard Weinstein, Cancer Prevention: Recent Progress sand Future Opportunities, Cancer Research, Vo. 51:5080s-5085s (1991).
Olli Simell, et al., Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance, Pediatr. Res., vol. 20:1117-1121 (1986).
Neish, et al., Phenylacetic Acid as a Potential Therapeutic Agent for the Treatment of Human Cancer, Experentia, vol. 27:860-861 (1971).
J.A. Stamatoyannopoulos, et al., Therapeutic Approaches to Hemoglobin Switching in Treatment of Hemoglobinopathies, Annu. Rev. Med., vol. 43:497-521 (1992).
Marcot et al., Chemical Abstracts, 83, 1975:53278s (1975).
Leary, Cancer Drug Also Helps in Treating Sickle Cell Anemia, Researchers Say, Atlanta Journal-Constitution, Thursday, Aug. 20, 1992.
Dvorit Samid, et al., Selective Growth Arrest and Phenotypic Reversion of Prostate Cancer Cells In Vitro by NonToxic Pharmacological Concentrations of Phenylacetate, The Journal of Clinical Investigation, vol. 91:2288-2295 (1993).
Dvorit Samid, et al., Induction of Erythroid Differentiation and Fetal Hemoglobin Production in Human Leukemic Cells Treated with Phenylacetate, Journal of the American Society of Hematology, vol. 80:1576-1581 (1992).
Dvorit Samid, et al., Phenylacetate: A Novel Nontoxic Inducer of Tumor Cell Differentiation, Cancer Research, vol. 52:1988-1992 (1992).
George J. Dover, et al., Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate, The New England Journal of Medicine, vol. 327:569-570 (1992).
Brusilow, S. W. and Horwich, A.L., Urea Cycle Enzymes, in Metabolic Basis of Inherited Diseases 629-633 (C.R. Scriver ed., 1989).
Shechter, Y. et al., Hydroxyphenyl Acetate Derivatives Inhibit Protein Tyrosine Kinase Activity and Proliferation in Nb2 Rat Lymphoma Cells and Insulin-Induced Lipogenesis in Rat Adipocytes, Molecular and Cellular Endocrinology, vol. 80, pp. 183-192 (1991).
Samid, D. et al., Interferon in Combination with Antitumourigenic Phenyl Derivatives: Potentiation of IFN.alpha. Activity In-Vitro, British J. Haematology, vol. 79, Supp. 1, pp. 81-83 (Oct. 10, 1991).
The Merck Index (Susan Budavari, et al. eds., 1989).
M.A. Smith, et al., Retinoids in Cancer Therapy, Journal of Clinical Oncology, 10:839-864 (1992).
R.L. Stephens, M.D., et al., Adriamycin and Cyclophosophamide Versus Hydroxyurea in Advanced Prostatic Cancer: A Randomized Southwest Oncology Group Study, Cancer 53:406-410 (1984).
Lejeune, F., et al., Disseminated melanoma, preclinical therapeutic studies, clinical trials, and patient treatment, Oncology 5:390-396 (1993).
Wuarin, L., et al., Effects of interferron-gamma and its interaction with retinoic acid on human neuroblastoma differentiation, Int. J. Cancer 48:136-141 (1991).
Hendrix, M.J.C., et al., Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor, Cancer Research 50:4121-4130 (1990).
Rudling, M.J., et al., Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement, Cancer Research 50:483-487 (1990).
Lando, M., et al., Modulation of intracellular cyclic adenosine monophosphate levels and the differentiation response of human neuroblastoma cells, Cancer Research 50:722-727 (1990).
Bloedow, C.E., Phase II studies of hydroxyurea (NSC-32065) in adults: micellaneous tumors, Cancer Chemotherapy Reports No. 40, pp. 39-41 (1964).
Kandutsch, A.A. and Saucier, S.E., Regulation of sterol synthesis in eveloping brains of normal and jimpy mice, Archives of Biochemistry and Biophysics 135:201-208 (1969).
Evans, A.E., et al., A Review of 17 IV-S Neuroblastoma Patients at the Children's Hospital of Philadelphia, Cancer 45:833-839 (1980).
Thiele, C. J., et al., Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma, Nature 313:404-406 (1985).
Giuffre, L., et al., Cyclic AMP induces differentiation in vitro of human melanoma cells, Cancer 61:1132-1141 (1988).
Nordenberg, J., et al., Growth inhibition of murine melanoma by butyric acid and dimethylsulfoxide, Experimental Cell Research 162:77-85 (1986).
Sidell, N., et al., Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines, Experimental Cell Research 148:21-30 (1983).
Questionable methods of cancer management: hydrogen peroxide and other `hyperoxygenation` therapies, Questionable Methods 43:47-56 (1993).
Finklestein, J.Z., et al., 13-c9s-retinoc acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the childrens cancer study group, Medical and pediatric Oncology 20:307-311 (1992).
Sidell, N. et al., Material and Methods, Exp. Cell Res. 148:22-30 (1983).
Nevinny, H.B. and Hall, T.C., Chemotherapy with hydroxyurea (NSC-32065) in renal cell carcinoma, J. Clinical Pharmacology, pp. 352-359 (Nov.-Dec. 1968).
Ariel, I.M., Therapeutic effects of hydroxyurea: experience with 118 patients with inoperable solid tumors, Cancer, pp. 705-714 (Mar. 1970).
Abemayor, E. and Sidell, N., Human neuroblastoma cell ines as models for the in vitro study of neoplastic and neuronal cell differentiation, Environmental Health Perspectives 80:3-15 (1989). J. Natl. Cancer Inst., 84(18):1398 (Sep. 16, 1992).
Ross, Philip D. and Subramanian, S., Inhibition of sickle cell hemoglobin gelation by some aromatic compounds, Biochem. Biophys. Res. Commun., 77:1217-1223 (1977).
Jones, G.L., Anti sickling effects of Betw Di Ethylaminoethylidiphenylpropyl acetate SFK-525-A, Pharmacologist, 20(3):204 (1978).
Erhum, Wilson O., Acetonyl esters of hydroxybenzoic acids as potential antisickling agents, Niger. J. Pharm., 12:285-287 (1981).
Abemayor, E. et al., Effects of retinoic acid on the in vivo growth of human neuroblastoma cells, Cancer Lett. (Netherlands), 55(1):1-5 (Nov. 19, 1990).
Cinatl, J. et al., In vitro differentiation of human
Nutter Nathan M.
The United States of America as represeneted by the Department o
LandOfFree
Compositions and methods for treating and preventing pathologies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating and preventing pathologies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating and preventing pathologies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396090